Adverse events with Gilead’s GS 9190 may increase HCV polymerase inhibitor scrutiny
This article was originally published in Scrip
Following the reports of two serious adverse events in two separate Phase IIb studies of GS 9190 in hepatitis C-infected patients, Gilead Sciences is amending the trial designs and discontinuing dosing of the drug candidate, following consultation with the US FDA.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.